by The global antidepressant drugs market size accounted for US$ 18.5 billion in 2023 and is projected to reach around USD 25.22 billion by 2033, growing at a CAGR of 3.20% from 2024 to 2033.
Key Takeaways
- North America contributed 46.50% market share in 2023.
- By product, the selective serotonin reuptake inhibitors segment dominated the market in 2023.
- By depressive disorder, the major depressive disorder segment is expected to sustain its dominance throughout the forecast period.
- By distribution channel, the offline segment held the largest share of the market in 2023.
- By distribution channel, the offline segment is observed to expand at the fastest rate during the forecast period.
Report Summary
The global antidepressant drugs market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the antidepressant drugs market across the globe.
A comprehensive estimate on the antidepressant drugs market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of antidepressant drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3698
Antidepressant Drugs Market Scope
| Report Coverage | Details |
| Global Market Size in 2023 | USD 18.5 Billion |
| Global Market Size by 2033 | USD 25.22 Billion |
| U.S. Market Size in 2023 | USD 6.02 Billion |
| U.S. Market Size by 2033 | USD 8.37 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product, By Depressive Disorder, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized antidepressant drugs market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Aspiration Tubing Market Size to Rise USD 11.46 Bn By 2033
Market Players
The report includes the profiles of key antidepressant drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Recent Developments
- In August 2023, The U.S. Food and Drug Administration (FDA) has approved ZURZUVAE 50 mg for individuals with postpartum depression (PPD), according to a statement from Biogen Inc. and Sage Therapeutics, Inc. For women with PPD, ZURZUVAE is the first and sole oral, once-daily, 14-day medication that can significantly reduce depression symptoms.
Antidepressant Drugs Market Companies
- GlaxoSmithKline PLC
- Sanofi
- AstraZeneca
- Eli Lilly and Company
- Pfizer Inc
Segments Covered in the Report
By Product
- Selective Serotonin Reuptake Inhibitors
- Serotonin Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressant
- Monoamine Oxidase Inhibitor
- Others
By Depressive Disorder
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Others.
By Distribution Channel
- Offline
- Online
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antidepressant Drugs Market
5.1. COVID-19 Landscape: Antidepressant Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antidepressant Drugs Market, By Product
8.1. Antidepressant Drugs Market Revenue and Volume, by Product, 2024-2033
8.1.1 Selective Serotonin Reuptake Inhibitors
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Serotonin Norepinephrine Reuptake Inhibitors
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Tricyclic Antidepressant
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Monoamine Oxidase Inhibitor
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Antidepressant Drugs Market, By Depressive Disorder
9.1. Antidepressant Drugs Market Revenue and Volume, by Depressive Disorder, 2024-2033
9.1.1. Major Depressive Disorder
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Obsessive-Compulsive Disorder
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Generalized Anxiety Disorder
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. Panic Disorder
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Antidepressant Drugs Market, By Distribution Channel
10.1. Antidepressant Drugs Market Revenue and Volume, by Distribution Channel, 2024-2033
10.1.1. Offline
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Online
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Antidepressant Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Depressive Disorder (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
Chapter 12. Company Profiles
12.1. GlaxoSmithKline PLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sanofi
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AstraZeneca
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Eli Lilly and Company
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer Inc
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
